SCHEMBL24253218

SCHEMBL24253218

CC(C)c1ccc(F)c2c1CCN(C)C2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.36
CHRNA7 P36544 1/20 0.36
MAOA P21397 2/20 0.35
MAOB P27338 2/20 0.35
ADRA2A P08913 2/20 0.33
ADRA2B P18089 2/20 0.33
ADRA2C P18825 2/20 0.33
ADRA1D P25100 1/20 0.33
ADRA1A P35348 1/20 0.33
ADRA1B P35368 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
NOTUM Q6P988 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
DRD3 P35462 2/20 0.33
HTR1A P08908 1/20 0.33
SLC6A2 P23975 1/20 0.33
HTR1D P28221 1/20 0.33
HTR1B P28222 1/20 0.33
HTR2A P28223 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3440774 0.84 MAOA (0.43) KDM4ECHRNA7MAOAMAOBADRA2A
SCHEMBL23551264 0.82 ALDH1A1 (0.34) KDM4ECHRNA7L3MBTL1PTGDR2
SCHEMBL25443997 0.80 PNMT (0.40) PTGDR2
SCHEMBL22993136 0.77 SLC6A2 (0.38) KDM4ECHRNA7MAOAMAOBADRA2A
SCHEMBL25091105 0.76 HTR2C (0.40) KDM4ECHRNA7MAOAMAOBADRA2A
SCHEMBL8184550 0.76 CYP2C19 (0.38) KDM4ECHRNA7MAOAMAOBADRA2A
SCHEMBL24253322 0.75 MAOA (0.42) CHRNA7MAOAMAOBADRA2AADRA2B
SCHEMBL24253238 0.73 ADRA2A (0.40) KDM4EMAOAMAOBADRA2AADRA2B
SCHEMBL12853675 0.73 SLC6A2 (0.37) MAOAMAOBNOTUMSLC6A2
SCHEMBL21195922 0.72 MAOA (0.48) MAOAMAOBCYP1A2CYP2D6NOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250080-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LTD (GB) 2023-08-10 US disclosed
US-20230250080-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LTD (GB) 2023-08-10 US disclosed
US-11613527-B2 Enzyme inhibitors KALVISTA PHARMACEUTICALS LIMITED (GB) 2023-03-28 US disclosed
US-20220048894-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250080-A1 ENZYME INHIBITORS SERPINB1, KLKB1, SERPINE1 KDM4E 1403/4885CHRNA7 3235/4885MAOA 175/4885
US-11613527-B2 Enzyme inhibitors SERPINB1, KLKB1, SERPINE1 KDM4E 1403/4885CHRNA7 3235/4885MAOA 175/4885
US-20220048894-A1 ENZYME INHIBITORS SERPINB1, KLKB1, SERPINE1 KDM4E 1403/4885CHRNA7 3235/4885MAOA 175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.